Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin
The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin will extend the lives of patients with squamous only non small cell lung cancer more than placebo plus Paclitaxel and Carboplatin.
Checked against the public recordLast updated Jun 18, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 3
- Sponsor
- Bristol-Myers Squibb
- Interventions being studied
- Drug: Ipilimumab; Drug: Placebo; Drug: Paclitaxel; Drug: Carboplatin
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: * Non small cell lung cancer (NSCLC) - squamous cell * Stage IV or recurrent NSCLC * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Exclusion Criteria: * Brain Metastases * Autoimmune diseases
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Sharp Memorial HospitalSan Diego, California
- Va Connecticut Healthcare SystemWest Haven, Connecticut
- Lynn Cancer Institute Center For Hematology-OncologyBoca Raton, Florida
- Integrated Community Oncology NetworkJacksonville, Florida
- University Of Illinois At Chicago Medical CenterChicago, Illinois
- Quincy Medical GroupQuincy, Illinois
- Presence Medical Group Hematology OncologySkokie, Illinois
- Southern Illinois University School Of MedicineSpringfield, Illinois
- St. Francis Hospital & Health CentersIndianapolis, Indiana
- Floyd Memorial Cancer Center Of IndianaNew Albany, Indiana
- Kentucky Cancer ClinicHazard, Kentucky
- Norton Cancer InstituteLouisville, Kentucky
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 18, 2020. Always confirm current availability with the study team.